Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
2 pending office actions • 1 art units • 2 examiners • 0 of 2 (0%) have an AI response strategy ready • 1 patents granted in the last 365 days
Genemedicine Co. Ltd. operates in Biotechnology & Pharmaceuticals with 2 pending office actions. Both of these actions are assigned to a distinct art unit. This concentration suggests that the company's biotech filings are closely related, allowing for a focused approach to the prior art within that unit.
There are 2 distinct examiners reviewing the portfolio. MOLOYE, TITILAYO is the busiest, with 1 pending office action. The use of 2 different examiners within the same art unit provides the company with multiple perspectives on its technology. This distribution requires the company to address the specific tendencies of two different officials.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 1 (50%) |
| Double-patenting + other | 1 (50%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| MOLOYE, TITILAYO | 1 | 62.5% | +47.9% |
| KIM, TAEYOON | 1 | 51.5% | +52.1% |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18955792 | ANTICANCER COMPOSITION COMPRISING RECOMBINANT ADENOVIRUS EXPRESSING DEGRADATION FACTOR FOR EXTRACELLULAR MATRIX | MOLOYE, TITILAYO | — |
| 17745768 | ANTICANCER COMPOSITION COMPRISING TUMOR-SPECIFIC ONCOLYTIC ADENOVIRUS AND IMMUNE CHECKPOINT INHIBITOR | KIM, TAEYOON | — |
| Art Unit | Apps |
|---|---|
| 1631 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18955792 | ANTICANCER COMPOSITION COMPRISING RECOMBINANT ADENOVIRUS EXPRESSING DEGRADATION FACTOR FOR EXTRACELLULAR MATRIX | MOLOYE, TITILAYO | — | §103 | Non-Final OA | — | Pending | Nov 21, 2024 |
| 17745768 | ANTICANCER COMPOSITION COMPRISING TUMOR-SPECIFIC ONCOLYTIC ADENOVIRUS AND IMMUNE CHECKPOINT INHIBITOR | KIM, TAEYOON | 1631 | §103DP | Non-Final OA | — | Pending | May 16, 2022 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial